The Effects of DPP4 Inhibitors on Lipid Status and Blood Pressure in Rats with Diabetes Mellitus Type 2
Open Access
- 1 December 2019
- journal article
- Published by Walter de Gruyter GmbH in Serbian Journal of Experimental and Clinical Research
- Vol. 20 (4) , 301-307
Abstract
The aim of the present study was to examine, evaluate and compare the effects of administered dipeptidyl peptidase-4 (DPP4) inhibitors saxagliptin and sitagliptin on lipid status parameters and blood pressure in rats with streptozotocine induced diabetes mellitus type 2. Forty-eight Wistar albino rats were divided randomly into 4 groups: 1. group I: control healthy group; 2. group II: rats with diabetes mellitus type 2; 3. group III: rats with diabetes mellitus type 2+ treated with 0.6 mg/kg of sitagliptin; 4. group IV: rats with diabetes mellitus type 2 treated with 0.45 mg/kg of saxagliptin. The rats from experimental groups were fed with a high-fat diet for 4 weeks and after 6–8 h of starvation received one dose of streptozotocin (STZ) intraperitoneally (25 mg/kg body weight) to induce type 2 diabetes mellitus (T2DM). Animals with fasting glucose above 7 mmol/L and insulin over 6 mmol/L were included in the study as rats with T2DM. Upon completion of the experiments, the blood was collected from the anesthetized animals and serum triglyceride (TG), total cholesterol (TCH), high density lipoprotein (HDL), and low density lipoprotein (LDL) were measured using spectrophotometry and commercial kits. At the beginning of the study and the day before sacrificing animals, the blood pressure and heart rate were measured by a tail-cuff noninvasive method. DPP4 inhibitors, as glucagon-like peptide-1 (GLP-1) agonists, were associated with modest reductions in DBP, LDL-C, TCH, and TGL and significant improvement in HDL, SBP and HR.Keywords
This publication has 38 references indexed in Scilit:
- Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitorBMC Pharmacology, 2012
- The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 DiabetesJournal of Korean Medical Science, 2012
- Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based TherapiesCurrent Atherosclerosis Reports, 2010
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in HumansHypertension, 2010
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008
- Diabetes and hypertensionNature Clinical Practice Endocrinology & Metabolism, 2007
- Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in AdipocytesJournal of Biological Chemistry, 2007
- Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IVCritical Reviews in Clinical Laboratory Sciences, 2003
- Dipeptidyl Peptidase IV in Human T LymphocytesScandinavian Journal of Immunology, 1989
- Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.Journal of Clinical Investigation, 1981